Canada markets closed

Amarin Corporation plc (AMRN)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
4.9600+0.0300 (+0.61%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close4.9300
Open4.9000
Bid5.0500 x 3100
Ask5.0800 x 28000
Day's Range4.7900 - 4.9750
52 Week Range3.3600 - 9.2500
Volume7,904,713
Avg. Volume4,162,758
Market Cap1.958B
Beta (5Y Monthly)2.25
PE Ratio (TTM)2,480.00
EPS (TTM)0.0020
Earnings DateAug. 02, 2021 - Aug. 06, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.13
  • Further Insights into Mechanism of Action of Icosapent Ethyl and Its Unique Form of Eicosapentaenoic Acid (EPA) Presented at the European Atherosclerosis Society (EAS) Congress 2021
    GlobeNewswire

    Further Insights into Mechanism of Action of Icosapent Ethyl and Its Unique Form of Eicosapentaenoic Acid (EPA) Presented at the European Atherosclerosis Society (EAS) Congress 2021

    Studies support potentially important anti-inflammatory, protein modulation, and cell function effects of icosapent ethyl as known by the brand name VASCEPA® in much of the world and as VAZKEPA in EuropeDUBLIN, Ireland and BRIDGEWATER, N.J., June 02, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the presentation of further insights into various potential mechanisms of action of icosapent ethyl and differences in biological actions of the unique form of eicosapenta

  • Why Amarin Trounced the Market on Tuesday
    Motley Fool

    Why Amarin Trounced the Market on Tuesday

    Amarin (NASDAQ: AMRN) rose to end Tuesday nearly 5.1% higher after the company provided details from clinical studies of the components of its one commercialized drug. In the presentation, the biotech company's Chief Scientific Officer Steven Ketchum highlighted the company's pronouncement that in the REDUCE-IT study gauging the efficacy of its product, it "significantly reduced first and total primary and key secondary endpoint events by approximately 30% to 40% in patients with dyslipidemia." Speaking of the key ingredient in Vascepa, Ketchum said that "we are hopeful that our continued support of robust scientific presentation of the clinical effects and unique multifactorial mechanisms of action of icosapent ethyl will lead to a greater understanding and usage of this important product to help appropriate at-risk patients."

  • Amarin to Present at Two Investor Conferences in June 2021
    GlobeNewswire

    Amarin to Present at Two Investor Conferences in June 2021

    DUBLIN, Ireland and BRIDGEWATER, N.J., May 18, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin's president and chief executive officer, and Karim Mikhail, Amarin’s senior vice president and head of commercial for Europe and future president and chief executive officer, are scheduled to present at the following investor conferences scheduled in June: Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 9:30 a.m. Eastern TimeGoldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8, 2021 at 10:30 a.m. Eastern Time Live audio webcasts of the presentations will be available at: http://www.amarincorp.com, and will be accessible at the same link for 30 days. About Amarin Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our scientific research foundation to our focus on clinical trials, and now our commercial expansion, we are evolving and growing rapidly. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, and Zug in Switzerland as well as commercial partners and suppliers around the world. We are committed to rethinking cardiovascular risk through the advancement of scientific understanding of the impact on society of significant residual risk that exists beyond traditional therapies, such as statins for cholesterol management. Availability of Other Information About AmarinInvestors and others should note that Amarin communicates with its investors and the public using the company website (www.amarincorp.com), the investor relations website (investor.amarincorp.com), including but not limited to investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media, and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933. Amarin Contact Information Investor Inquiries:Investor RelationsAmarin Corporation plcIR@amarincorp.com (investor inquiries) Solebury Troutamarinir@troutgroup.com Media Inquiries:CommunicationsAmarin Corporation plcIn U.S.: +1 (908) 892-2028 PR@amarincorp.com (media inquiries)